{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T15:34:02Z","timestamp":1772292842081,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Math. Biol."],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00285-018-1262-6","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T10:48:38Z","timestamp":1531219718000},"page":"1533-1561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Optimization of combination therapy for chronic myeloid leukemia with dosing constraints"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2185-2785","authenticated-orcid":false,"given":"Helen","family":"Moore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6447-1958","authenticated-orcid":false,"given":"Urszula","family":"Ledzewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"issue":"3","key":"1262_CR1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1006\/bulm.1999.0165","volume":"62","author":"EK Afenya","year":"2000","unstructured":"Afenya EK, Calder\u00f3n C (2000) Diverse ideas on the growth kinetics of disseminated cancer cells. Bull Math Biol 62(3):527\u2013542","journal-title":"Bull Math Biol"},{"key":"1262_CR2","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041\u20136051","journal-title":"J Clin Oncol"},{"issue":"2","key":"1262_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3934\/mbe.2012.9.241","volume":"9","author":"MV Barbarossa","year":"2012","unstructured":"Barbarossa MV, Kuttler C, Zinsl J (2012) Delay equations modeling the effects of phase-specific drugs and immunotherapy on proliferating tumor cells. Math Biosci Eng 9(2):241\u2013257","journal-title":"Math Biosci Eng"},{"issue":"31","key":"1262_CR4","doi-asserted-by":"publisher","first-page":"E6277","DOI":"10.1073\/pnas.1703355114","volume":"114","author":"S Barish","year":"2017","unstructured":"Barish S, Ochs MF, Sontag ED, Gevertz JL (2017) Evaluating optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy. PNAS 114(31):E6277\u2013E6286. https:\/\/doi.org\/10.1073\/pnas.1703355114","journal-title":"PNAS"},{"key":"1262_CR5","volume-title":"Singular trajectories and their role in control theory. Math\u00e9matiques & Applications","author":"B Bonnard","year":"2003","unstructured":"Bonnard B, Chyba M (2003) Singular trajectories and their role in control theory. Math\u00e9matiques & Applications, vol 40. Springer, Paris"},{"key":"1262_CR6","volume-title":"Introduction to the mathematical theory of control","author":"A Bressan","year":"2007","unstructured":"Bressan A, Piccoli B (2007) Introduction to the mathematical theory of control. American Institute of Mathematical Sciences (AIMS), Providence"},{"key":"1262_CR7","unstructured":"Bristol-Myers Squibb (2000) A phase 1B study to investigate the safety and preliminary efficacy for the combination of dasatinib plus nivolumab in patients with chronic myeloid leukemia. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda, MD. [cited 2016 Mar 7]. http:\/\/clinicaltrials.gov\/show\/NCT02011945"},{"issue":"2","key":"1262_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11538-005-9014-3","volume":"68","author":"F Castiglione","year":"2006","unstructured":"Castiglione F, Piccoli B (2006) Optimal control in a model of dendritic cell transfection cancer immunotherapy. Bull Math Biol 68(2):255\u2013274","journal-title":"Bull Math Biol"},{"issue":"Suppl 2","key":"1262_CR9","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","volume":"94","author":"B Chereda","year":"2015","unstructured":"Chereda B, Melo JV (2015) Natural course and biology of CML. Ann Hematol 94(Suppl 2):S107\u2013S121","journal-title":"Ann Hematol"},{"key":"1262_CR10","unstructured":"Dasatinib (2006) [package insert] Bristol-Myers Squibb Company, Princeton. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021986s7s8lbl.pdf"},{"issue":"4","key":"1262_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jtbi.2005.06.037","volume":"238","author":"LG Pillis de","year":"2006","unstructured":"de Pillis LG, Gu W, Radunskaya AE (2006) Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. J Theor Biol 238(4):841\u2013862","journal-title":"J Theor Biol"},{"key":"1262_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10928-014-9386-9","volume":"41","author":"LG Pillis de","year":"2014","unstructured":"de Pillis LG, Eladdadi A, Radunskaya AE (2014) Modeling cancer-immune responses to therapy. J Pharmacokinet Pharmacodyn 41:461\u2013478","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1262_CR13","first-page":"1126","volume":"22","author":"M Deininger","year":"2009","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Hatfield AK, Mone M, Filian J, Reynolds J, Gathmann I, Larson RA, Druker BJ (2009) International randomized study of interferon vs STI571 (IRIS) 8-year follow up. ASH Annu Meet Abstr 22:1126","journal-title":"ASH Annu Meet Abstr"},{"key":"1262_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.physd.2005.06.032","volume":"208","author":"A d\u2019Onofrio","year":"2005","unstructured":"d\u2019Onofrio A (2005) A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences. Physica D Nonlinear Phenom 208:220\u2013235","journal-title":"Physica D Nonlinear Phenom"},{"key":"1262_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.801","author":"S Dulucq","year":"2016","unstructured":"Dulucq S, Mahon F-X (2016) Deep molecular responses for treatment-free remission in chronic myeloid leukemia. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.801","journal-title":"Cancer Med"},{"issue":"3","key":"1262_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, O\u2019Brien S, Kurzrock R, Kantarjian H (1999) The biology of chronic myeloid leukemia. N Engl J Med 341(3):164\u2013172","journal-title":"N Engl J Med"},{"key":"1262_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","volume":"14","author":"S Farkona","year":"2016","unstructured":"Farkona S, Diamandis D, Blasutig I (2016) Cancer immunotherapy: the beginning of the end of cancer? BMC Med 14:73","journal-title":"BMC Med"},{"key":"1262_CR18","first-page":"2084","volume":"51","author":"AS Fokas","year":"1999","unstructured":"Fokas AS, Keller JB, Clarkson BD (1999) Mathematical model of granulocytopoesis and chronic myelogeneous leukemia. Cancer Res 51:2084\u20132091","journal-title":"Cancer Res"},{"key":"1262_CR19","unstructured":"Imatinib (2001) [package insert] Novartis Pharma Stein AG, Stein. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021588s024lbl.pdf"},{"key":"1262_CR20","unstructured":"Ishida Y, Murai K, Yamaguchi K, Miyagishima T, Shindo M, Ogawa K, Nagashima T, Sato S, Watanabe R, Yamamoto S, Hirose T, Saitou S, Yonezumi M, Kondo T, Kato Y, Mochizuki N, Ohno K, Kishino S, Kubo K, Oyake T, Ito S, the Inter-Michinoku Dasatinib Study Group (IMIDAS) (2016) Pharmacokinetics and pharmacodynamics of dastinib in the chronic phase of newly diagnosed chronic myeloid leukemia. Eur J Pharmacol 72:185\u2013193"},{"key":"1262_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s002850050127","volume":"37","author":"D Kirschner","year":"1998","unstructured":"Kirschner D, Panetta JC (1998) Modeling immunotherapy of the tumor-immune interaction. J Math Biol 37:235\u2013252","journal-title":"J Math Biol"},{"issue":"2","key":"1262_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3934\/mbe.2011.8.289","volume":"8","author":"NL Komarova","year":"2011","unstructured":"Komarova NL (2011) Mathematical modeling of cyclic treatments of chronic myeloid leukemia. Math Biosci Eng 8(2):289\u2013306","journal-title":"Math Biosci Eng"},{"issue":"5","key":"1262_CR23","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2009-12-256800","volume":"116","author":"A Kreutzman","year":"2010","unstructured":"Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, Porkka K, Mustjoki S (2010) Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 116(5):771\u2013782","journal-title":"Blood"},{"key":"1262_CR24","first-page":"17","volume":"1","author":"A Kreutzman","year":"2013","unstructured":"Kreutzman A, Porkka K, Mustjoki S (2013) Immunomodulatory effects of tyrosine kinase inhibitors. Int Trends Immunol 1:17\u201328","journal-title":"Int Trends Immunol"},{"issue":"3","key":"1262_CR25","doi-asserted-by":"publisher","first-page":"e28925","DOI":"10.4161\/onci.28925","volume":"29","author":"A Kreutzman","year":"2014","unstructured":"Kreutzman A, Ilander M, Porkka K, Vakkila J, Mustjoki S (2014) Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. Oncoimmunology 29(3):e28925","journal-title":"Oncoimmunology"},{"issue":"10","key":"1262_CR26","first-page":"1","volume":"5","author":"N Kronik","year":"2010","unstructured":"Kronik N, Kogan Y, Elishmereni M, Halevi-Tobias K, Vuk-Pavlovi\u0107 S, Agur Z (2010) Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models. PLoS ONE 5(10):1\u20138","journal-title":"PLoS ONE"},{"key":"1262_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/app6100291","volume":"6","author":"U Ledzewicz","year":"2016","unstructured":"Ledzewicz U, Moore H (2016) Dynamical systems properties of a mathematical model for treatment of CML. Appl Sci 6:291. https:\/\/doi.org\/10.3390\/app6100291","journal-title":"Appl Sci"},{"issue":"1","key":"1262_CR28","first-page":"331","volume":"23","author":"U Ledzewicz","year":"2018","unstructured":"Ledzewicz U, Moore H (2018) Optimal control applied to a generalized Michaelis-Menten model of CML therapy. Discrete Contin Dyn Syst Ser B 23(1):331\u2013346","journal-title":"Discrete Contin Dyn Syst Ser B"},{"key":"1262_CR29","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3934\/dcdsb.2013.18.1031","volume":"18","author":"U Ledzewicz","year":"2013","unstructured":"Ledzewicz U, Faraji Mosalman MS, Sch\u00e4ttler H (2013) Optimal controls for a mathematical model of tumor-immune interactions under targeted chemotherapy with immune boost. Discrete Contin Dyn Syst Ser B 18:1031\u20131051. https:\/\/doi.org\/10.3934\/dcdsb.2013.18.1031","journal-title":"Discrete Contin Dyn Syst Ser B"},{"issue":"3","key":"1262_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5581\/1516-8484.20110056","volume":"33","author":"MP Machado","year":"2011","unstructured":"Machado MP, Tomaz JP, Lorand-Metze I, de Souza CA, Vigorito AC, Delamain MT, Bendit I, Pereira NF, Barbosa Pagnano KB (2011) Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response. Rev Bras Hematol Hemoter 33(3):211\u2013215. https:\/\/doi.org\/10.5581\/1516-8484.20110056","journal-title":"Rev Bras Hematol Hemoter"},{"key":"1262_CR31","unstructured":"Mahon F-X, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P, on behalf of the Intergroupe Fran\u00e7ais des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques (FILMC) (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11): 1029\u20131035"},{"key":"1262_CR32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jtbi.2003.11.024","volume":"227","author":"H Moore","year":"2004","unstructured":"Moore H, Li NK (2004) A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. J Theor Biol 227:513\u2013523","journal-title":"J Theor Biol"},{"key":"1262_CR33","unstructured":"Moore H, Strauss L, Ledzewicz U (2015) Mathematical optimization of combination therapy for chronic myeloid leukemia (CML). A poster presented at the 6th American conference on pharmacometrics (ACoP), Crystal City, VA, 4\u20137 October"},{"key":"1262_CR34","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1242\/dev.106575","volume":"141","author":"A Nakamura-Ishizu","year":"2014","unstructured":"Nakamura-Ishizu A, Takizawa H, Suda T (2014) The analysis, roles and regulation of quiescence in hematopoietic stem cells. Development 141:4656\u20134666","journal-title":"Development"},{"key":"1262_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.mbs.2007.05.003","volume":"210","author":"S Nanda","year":"2007","unstructured":"Nanda S, Moore H, Lenhart S (2007) Optimal control of treatment in a mathematical model of chronic myelogenous leukemia. Math Biosci 210:143\u2013156","journal-title":"Math Biosci"},{"key":"1262_CR36","unstructured":"Nivolumab (2014) [package insert] Bristol-Myers Squibb Company, Princeton. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125554lbl.pdf"},{"issue":"4","key":"1262_CR37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264","journal-title":"Nat Rev Cancer"},{"key":"1262_CR38","volume-title":"The mathematical theory of optimal processes","author":"LS Pontryagin","year":"1964","unstructured":"Pontryagin LS, Boltyanskii VG, Gamkrelidze RV, Mishchenko EF (1964) The mathematical theory of optimal processes. MacMillan, New York"},{"key":"1262_CR39","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","volume":"107","author":"RD Press","year":"2006","unstructured":"Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, Mori M, Mauro MJ, Deininger MW, Druker BJ (2006) BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 107:4250\u20134256. https:\/\/doi.org\/10.1182\/blood-2005-11-4406","journal-title":"Blood"},{"issue":"1","key":"1262_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12154-009-0029-3","volume":"3","author":"H Prinz","year":"2010","unstructured":"Prinz H (2010) Hill coefficients, dose-response curves and allosteric mechanisms. J Chem Biol 3(1):37\u201344","journal-title":"J Chem Biol"},{"issue":"4","key":"1262_CR41","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122(4):515\u2013522","journal-title":"Blood"},{"key":"1262_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1083\/jcb.43.1.32","volume":"43","author":"SI Rubinow","year":"1969","unstructured":"Rubinow SI (1969) A simple model of steady state differentiating cell system. J Cell Biol 43:32\u201339","journal-title":"J Cell Biol"},{"key":"1262_CR43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF01273744","volume":"1","author":"SI Rubinow","year":"1975","unstructured":"Rubinow SI, Lebowitz JL (1975) A mathematical model of neutrophil production and control in normal men. J Math Biol 1:187\u2013225","journal-title":"J Math Biol"},{"issue":"17","key":"1262_CR44","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340(17):1330\u20131340","journal-title":"N Engl J Med"},{"key":"1262_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-3834-2","volume-title":"Geometric optimal control","author":"H Sch\u00e4ttler","year":"2012","unstructured":"Sch\u00e4ttler H, Ledzewicz U (2012) Geometric optimal control. Springer, New York"},{"key":"1262_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-2972-6","volume-title":"Optimal control for mathematical models of cancer therapies","author":"H Sch\u00e4ttler","year":"2015","unstructured":"Sch\u00e4ttler H, Ledzewicz U (2015) Optimal control for mathematical models of cancer therapies. Springer, New York"},{"issue":"17","key":"1262_CR47","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.1158\/0008-5472.CAN-15-3567","volume":"76","author":"R Serre","year":"2016","unstructured":"Serre R, Benzekry S, Padovani L, Meille C, Andr\u00e9 N, Ciccolini J, Barlesi F, Muracciole X, Barbolosi D (2016) Mathematical modeling of cancer immunotherapy and its synergy with radiotherapy. Cancer Res 76(17):4931\u20134940","journal-title":"Cancer Res"},{"issue":"10","key":"1262_CR48","doi-asserted-by":"publisher","first-page":"e76195","DOI":"10.1371\/journal.pone.0076195","volume":"8","author":"L Shahriyari","year":"2013","unstructured":"Shahriyari L, Komarova NL (2013) Symmetric vs. asymmetric stem cell divisions: an adaptation against cancer? PLoS ONE 8(10):e76195. https:\/\/doi.org\/10.1371\/journal.pone.0076195","journal-title":"PLoS ONE"},{"issue":"3","key":"1262_CR49","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/135965350901400306","volume":"14","author":"E Shudo","year":"2009","unstructured":"Shudo E, Ribeiro RM, Perelson AS (2009) Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antiviral Therapy 14(3):459\u201364","journal-title":"Antiviral Therapy"},{"key":"1262_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/oca.704","volume":"23","author":"RF Stengel","year":"2002","unstructured":"Stengel RF, Ghigliazza R, Kulkarni N, Laplace O (2002) Optimal control of innate immune response. Optim Control Appl Methods 23:91\u2013104","journal-title":"Optim Control Appl Methods"},{"key":"1262_CR51","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/1097-0142(19870201)59:3+<664::AID-CNCR2820591316>3.0.CO;2-Y","volume":"59","author":"M Talpaz","year":"1987","unstructured":"Talpaz M, Kantarjian H, McCredie K, Trujillo J, Keating M, Gutterman JU (1987) Therapy of chronic myelogenous leukemia. Cancer 59:664\u2013667","journal-title":"Cancer"},{"issue":"25","key":"1262_CR52","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","volume":"304","author":"Paul L. Weiden","year":"1981","unstructured":"Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, Seattle Marrow Transplant Team (1981) Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529\u20131533","journal-title":"New England Journal of Medicine"},{"key":"1262_CR53","volume-title":"The biology of cancer","author":"RA Weinberg","year":"2007","unstructured":"Weinberg RA (2007) The biology of cancer. Taylor & Francis, New York"},{"issue":"7","key":"1262_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11538-012-9722-4","volume":"74","author":"S Wilson","year":"2012","unstructured":"Wilson S, Levy D (2012) A mathematical model of the enhancement of tumor vaccine efficacy by immunotherapy. Bull Math Biol 74(7):1\u201320","journal-title":"Bull Math Biol"}],"container-title":["Journal of Mathematical Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00285-018-1262-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00285-018-1262-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00285-018-1262-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T04:52:06Z","timestamp":1661575926000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00285-018-1262-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["1262"],"URL":"https:\/\/doi.org\/10.1007\/s00285-018-1262-6","relation":{},"ISSN":["0303-6812","1432-1416"],"issn-type":[{"value":"0303-6812","type":"print"},{"value":"1432-1416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,10]]},"assertion":[{"value":"1 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}